NASDAQ$ACRS
Aclaris Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Aclaris Therapeutics reported its Q3 2024 financial results, marking the dosing of the first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis.
Aclaris Therapeutics reported a decrease in revenue for the third quarter of 2024, primarily driven by lower milestone payments compared to the previous year. The company highlighted the dosing of the first patient in the Phase 2a trial of ATI-2138 for atopic dermatitis and anticipates top-line data in the first half of 2025.
- First patient dosed in the Phase 2a trial of ATI-2138 for atopic dermatitis.
- Aclaris is progressing a second-generation ITK selective inhibitor to development candidate selection for autoimmune indications.
- Aclaris is seeking a global development and commercialization partner for lepzacitinib (excluding Greater China).
- Aclaris plans to support investigator-initiated trials of zunsemetinib for pancreatic and metastatic breast cancer.
Headline financials
Revenue & EPS history
Aclaris Therapeutics · Revenue · Quarterly
$4.35M
Revenue by segment
Aclaris Therapeutics · $9.28M total across 2 segments · Q3 2023
- Licensing$8.58M-52.1%92.4%
- Contract research$705K-35.3%7.6%
Forward guidance
Aclaris anticipates that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund its operations into 2028, without giving effect to any potential business development transactions, financing activities or the outcome of its strategic review.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.7%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+22.7%
Q4 2018
Best reaction
-15.3%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +1.9% | -8.8% | |
| Q4 2025 | -5.2% | -8.2% | +6.3% | |
| Q3 2025 | -4.7% | -9.7% | +23.7% | |
| Q1 2025 | -0.8% | -3.8% | +9.9% | |
| Q4 2024 | -7.1% | -8.1% | -24.3% | |
| Q3 2024 | +10.4% | +18.5% | +77.5% | |
| Q2 2024 | -4.1% | -6.6% | -4.1% | |
| Q1 2024 | -6.9% | -10.7% | -21.4% | |
| Q4 2023 | -1.7% | +2.5% | +2.5% | |
| Q3 2023 | +0.9% | -11.5% | -81.0% | |
| Q2 2023 | -12.1% | -16.5% | -23.4% | |
| Q1 2023 | -7.8% | -12.1% | +4.5% | |
| Q4 2022 | -4.9% | -1.8% | -36.9% | |
| Q3 2022 | +4.3% | +9.3% | -0.2% | |
| Q2 2022 | +18.1% | +26.8% | +20.6% | |
| Q1 2022 | -8.9% | -4.5% | +35.3% | |
| Q4 2021 | +14.3% | +11.3% | +33.5% | |
| Q3 2021 | -12.4% | -11.0% | -31.4% | |
| Q2 2021 | +4.1% | +1.4% | +21.2% | |
| Q1 2021 | -2.2% | -8.6% | -8.8% | |
| Q4 2020 | +7.8% | +12.5% | +11.4% | |
| Q3 2020 | +7.0% | +7.5% | +0.8% | |
| Q2 2020 | +11.3% | +12.8% | +9.7% | |
| Q1 2020 | +12.7% | +10.3% | +13.5% | |
| Q4 2019 | -14.0% | -20.3% | -18.2% | |
| Q3 2019 | +20.4% | +11.7% | +2.5% | |
| Q2 2019 | -11.8% | -18.8% | -1.0% | |
| Q1 2019 | -11.2% | -14.7% | -29.0% | |
| Q4 2018 | +22.7% | +8.7% | -7.8% | |
| Q3 2018 | -1.8% | -13.2% | -29.8% | |
| Q2 2018 | -4.6% | -3.9% | -11.9% | |
| Q1 2018 | -0.5% | +4.2% | +1.4% | |
| Q4 2017 | -6.7% | -12.5% | -18.4% | |
| Q3 2017 | -5.7% | -3.2% | -7.9% | |
| Q2 2017 | -0.1% | -7.1% | +1.4% | |
| Q1 2017 | +6.3% | +5.8% | +0.6% | |
| Q4 2016 | -4.9% | -5.2% | +5.8% | |
| Q3 2016 | -1.0% | -2.7% | +39.7% | |
| Q2 2016 | +3.1% | +7.0% | +15.0% | |
| Q1 2016 | -15.3% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro